Last reviewed · How we verify
NCT07515404: CFPP
A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study
trial in Plasmapheresis in 3 participants. Completed in 1 February 2026.
1 February 2026
Quick facts
| Lead sponsor | Centre Hospitalier Régional Metz-Thionville |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3 |
| Start date | 1 January 2026 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across France |
Conditions studied
- Plasmapheresis — all drugs for Plasmapheresis →
Sponsor
Centre Hospitalier Régional Metz-Thionville
Who can join
18 and older, any sex, with Plasmapheresis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Global demand for therapeutic plasmapheresis is rising to treat various immunological, rheological, and lipoprotein-related disorders. Traditional therapeutic plasma exchange (TPE) removes plasma entirely and replaces it with costly substitution fluids, making it less sustainable. Semi-specific methods like plasma adsorption and double-filtration plasmapheresis (DFPP) avoid this by purifying and reinfusing the patient's own plasma. DFPP, although effective and widely reimbursed in Europe and Asia, relies on membrane-based plasma separation systems that require high blood flow rates and offer limited plasma extraction efficiency, which prolongs treatment and often necessitates central venous access. Centrifugation-based systems allow lower blood flow rates and higher plasma extraction ratios, but existing devices are not designed for automated double-cascade plasmapheresis. To address these limitations, our department has implemented a new strategy: Centrifugation and Filtration Plasmapheresis (CFPP), which combines centrifugation for initial plasma separation with membrane filtration for secondary purification. CFPP maintains the safety and efficacy of DFPP while offering key advantages: easier peripheral venous access, shorter procedures, no need for replacement fluids, and reinfusion of purified autologous plasma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07515404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Plasmapheresis
Currently open trials in the same condition.
- NCT05562960 — Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP · NA · recruiting
Other Centre Hospitalier Régional Metz-Thionville trials
Trials by the same sponsor.
- NCT07435389 — VENTILATION DURING SPACEFLIGHT (PHASE 2) · NA · not yet recruiting
- NCT07405996 — Referral of Patients With Biological Abnormalities to an Emergency Department · not yet recruiting
- NCT07406022 — Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. · not yet recruiting
- NCT07390604 — Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patien · completed
- NCT06972355 — Efficacy of Treadmill Walking With Hidden Vision for Rehabilitation in the Subacute Phase of Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07515404 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07515404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing